Autopsy report · NCT00054405

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Administratively complete.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months after it had already started.
40 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: National Cancer Institute (NCI)
Sponsor type: US National Institutes of Health
Conditions: Recurrent Neuroblastoma
Interventions: recombinant interleukin-12; aldesleukin
Participants: 40
Sites: 14
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.